Skip to main
BLLN

Billiontoone Inc (BLLN) Stock Forecast & Price Target

Billiontoone Inc (BLLN) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 29%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

BillionToOne is a molecular diagnostics company with a strong presence in the prenatal and oncology testing markets. Their QCT platform and conservative decision-making culture give them a competitive edge. With accretive contracts and favorable payment rates from private payors, the company is expected to continue its strong growth and profitability, despite potential risks from PAMA implementation. Partnerships and new tests, like the Unity Confirm fetal cell assay, are expected to drive further expansion.

Bears say

BillionToOne is facing significant risks including limitations in the growth of the prenatal market, competition in the therapy selection market, and potential limitations of its technology platform in highly competitive pipeline markets. Additionally, while the company has raised its revenue guidance for 2026, it has not included potential future limitations in its projections. Finally, the recent announcement of the upcoming launch of UNITY Confirm may provide a market share increase opportunity but may not significantly impact the company's overall revenue.

Billiontoone Inc (BLLN) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 29% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Billiontoone Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Billiontoone Inc (BLLN) Forecast

Analysts have given Billiontoone Inc (BLLN) a Buy based on their latest research and market trends.

According to 7 analysts, Billiontoone Inc (BLLN) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Billiontoone Inc (BLLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.